SCHEMBL5011975

SCHEMBL5011975

O=C1Nc2ccc(Cl)cc2/C1=C\Nc1ccc(CO)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.56
TDO2 P48775 2/20 0.56
TGM2 P21980 3/20 0.55
LRRK2 Q5S007 7/20 0.50
PSEN1 P49768 4/20 0.50
PSEN2 P49810 4/20 0.50
APH1B Q8WW43 4/20 0.50
NCSTN Q92542 4/20 0.50
APH1A Q96BI3 4/20 0.50
PSENEN Q9NZ42 4/20 0.50
CDYL2 Q8N8U2 1/20 0.47
CDYL Q9Y232 1/20 0.47
CDY1; CDY1B Q9Y6F8 1/20 0.47
PDGFRB P09619 2/20 0.46
CES1 P23141 1/20 0.46
RPS6KA3 P51812 1/20 0.45
EGFR P00533 1/20 0.45
ERBB2 P04626 1/20 0.45
RET P07949 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5011977 1.00 IDO1 (0.56) IDO1TDO2TGM2LRRK2PSEN1
SCHEMBL6683977 0.88 IDO1 (0.45) IDO1TDO2TGM2LRRK2PSEN1
SCHEMBL6683982 0.88 IDO1 (0.45) IDO1TDO2TGM2LRRK2PSEN1
SCHEMBL4987869 0.88 IDO1 (0.56) IDO1TDO2TGM2LRRK2PSEN1
SCHEMBL4987873 0.88 IDO1 (0.56) IDO1TDO2TGM2LRRK2PSEN1
SCHEMBL4998578 0.87 IDO1 (0.56) IDO1TDO2TGM2LRRK2PSEN1
SCHEMBL4998576 0.87 IDO1 (0.56) IDO1TDO2TGM2LRRK2PSEN1
SCHEMBL4994537 0.86 NTRK1 (0.46) IDO1TDO2TGM2RPS6KA3
SCHEMBL4994533 0.86 NTRK1 (0.46) IDO1TDO2TGM2RPS6KA3
SCHEMBL6843741 0.86 IDO1 (0.55) IDO1TDO2TGM2LRRK2PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 IDO1 404/4885TDO2 806/4885TGM2 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.